Issue 1, 2014

Precursor-directed biosynthesis of micacocidin derivatives with activity against Mycoplasma pneumoniae

Abstract

Micacocidin is a promising natural product for the treatment of Mycoplasma pneumoniae infections. In the biosynthesis of this antibiotic, a fatty acid-AMP ligase (FAAL) activates the starter unit hexanoic acid as acyl-adenylate and forwards it to an iteratively acting polyketide synthase. Biochemical analysis of the FAAL revealed an extended substrate tolerance, thereby opening the door for the modification of a micacocidin residue that is barely accessible via semisynthesis. A total of six new analogues were generated by precursor-directed biosynthesis in this study and profiled against M. pneumoniae.

Graphical abstract: Precursor-directed biosynthesis of micacocidin derivatives with activity against Mycoplasma pneumoniae

Supplementary files

Article information

Article type
Paper
Submitted
09 Sep 2013
Accepted
25 Oct 2013
First published
31 Oct 2013

Org. Biomol. Chem., 2014,12, 113-118

Precursor-directed biosynthesis of micacocidin derivatives with activity against Mycoplasma pneumoniae

M. F. Kreutzer, H. Kage, J. Herrmann, J. Pauly, R. Hermenau, R. Müller, D. Hoffmeister and M. Nett, Org. Biomol. Chem., 2014, 12, 113 DOI: 10.1039/C3OB41839A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements